Skip to main content
SpringerLink
Log in
Book cover

Cancer Neutron Capture Therapy

  • Book
  • © 1996

Overview

Editors:
  1. Yutaka Mishima

    1. Mishima Institute for Dermatological Research, Kobe, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (126 chapters)

  1. Front Matter

    Pages i-xxvii
    Download chapter PDF

  3. Chemistry

    1. Macromolecular Species

      1. Recent Results with Liposomes as Boron Delivery Vehicles for Boron Neutron Capture Therapy
        • M. Frederick Hawthorne, Debra A. Feakes, Kenneth Shelly
        Pages 27-36
      2. Preparation of Epidermal Growth Factor Conjugates Aimed for Boron Neutron Capture Therapy
        • Lars Gedda, Pär Olsson, Jörgen Carlsson
        Pages 37-42
      3. Epidermal Growth Factor (EGF) as a Potential Targeting Agent for Delivery of Boron to Malignant Gliomas
        • Jacek Capala, Rolf F. Barth, Dianne M. Adams, Michael Q. Bailey, Albert H. Soloway, Jörgen Carlsson
        Pages 43-48
      4. Boron Neutron Capture Therapy Against Tumor Cells with Overexpression of the EGF-Receptor
        • Jörgen Carlsson, Lars Gedda, Christina Grönvik, Torbjörn Hartman, Annelie Lindström, Hans Lundqvist et al.
        Pages 49-56
      5. Boron-Rich Oligophosphates — Novel Molecules for Use in BNCT
        • Robert R. Kane, Karin Drechsel, Young Soo Kim, Cynthia L. Beno, Christine S. Lee, Gabriel Mendez et al.
        Pages 57-65
      6. Potential Use of Bispecific Antibodies (BSABS) for Targeting Gliomas and Melanomas
        • Liang Liu, Rolf F. Barth, Dianne M. Adams, Albert H. Soloway, Ralph A. Reisfeld
        Pages 67-73
      7. Effect of Intratumoral Injection of 10B-Immunoliposome on BNCT for Growth Inhibition of Human Pancreatic Cancer Grafts in Nude Mice
        • Hironobu Yanagië, Toshio Tomita, Hisao Kobayashi, Yuzo Fujii, Yoshiyuki Saegusa, Masazumi Eriguchi et al.
        Pages 75-79

    2. BPA and other Amino Acids

      1. Chemical Modeling with <i>p</i>-Boronophenylalanine for Boron Accumulation to and Release from Melanoma
        • Kazuo Yoshino, Yoshihiro Mori, Hidetake Kakihana, Hiroaki Takahashi, Yutaka Mishima, Masamitsu Ichihashi
        Pages 81-90
      2. Chemical Properties of <i>p</i>-, <i>m</i>-, <i>o</i>-Boronophenylalanine
        • Kazuo Yoshino, Nobuya Watanabe, Hiroaki Takahashi, Shinji Watanabe, Yoshihiro Mori, Masamitsu Ichihashi et al.
        Pages 91-97
      3. An Efficient Synthesis of <i>p</i>-Boronophenylalanine and Its Homologues by the Reaction of Ethyl Isocyanoacetate with a <i>p</i>-Formylbenzeneboronic Acid Derivative
        • Mitsunori Kirihata, Tsuguhiro Morimoto, Itsuo Ichimoto, Masao Takagaki
        Pages 99-104
      4. New Unnatural Boron-Containing Amino Acids and Peptides as Potential Delivery Agents for Neutron Capture Therapy
        • Iwona M. Wyzlic, John C. Beeson, Albert H. Soloway, Jinghong Yong, Rolf F. Barth
        Pages 105-110
      5. Study of the Interaction of P-Boronophenylalanine and Its Analogs with Various Carboxylic Acids by Using Zone Electrophoresis
        • Yoshinori Kitaoka, Mitsue Kobayashi, Keizo Kawamoto, Tsuguhiro Morimoto, Mitsunori Kirihata, Itsuo Ichimoto
        Pages 111-114
      6. Examination of Stability of <i>p-</i>, <i>m-</i>, <i>o-</i>Boronophenylalanine in Blood with High Performance Liquid Chromatography
        • Kazuo Yoshino, Naoko Koike, Yuko Kuroda, Yoshihiro Mori, Masamitsu Ichihashi, Hidetake Kakihana et al.
        Pages 115-120
      7. Synthesis and Initial Biological Evaluation of Carborane-Containing Phenanthridinium Derivatives
        • Werner Tjarks, Jonas Malmquist, Lars Gedda, Stefan Sjöberg, Jörgen Carlsson
        Pages 121-126
      8. Chemical Behavior of Boron-Containing Amino Acids for Neutron Capture Therapy in Aqueous Solutions
        • Mitsue Kobayashi, Yoshinori Kitaoka
        Pages 127-130

    3. Carborane Related

      1. Asymmetric Synthesis of <i>o</i>- and <i>p</i>-Carboranyl Amino Acids
        • Jonas Malmquist, Jörgen Carlsson, Karin E. Markides, Patrik Pettersson, Pär Olsson, Kerstin Sunnerheim-Sjöberg et al.
        Pages 131-136
      2. Synthesis, Tissue Uptake, and Toxicity of a Nickel Tetracarboranylphenylporphyrin
        • Michiko Miura, Peggy L. Micca, Jason A. Donaldson, John C. Heinrichs, John A. Shelnutt, Gerald C. Finkel et al.
        Pages 137-141
      3. Optimization of Drug Anchor for <i>Ortho</i>-Carborane in Reconstitution of Low Density Lipoproteins for Neutron Capture Therapy
        • Michael D. Smith, Yohanes Setiawan, Douglas E. Moore
        Pages 143-149
Back to top

Keywords

About this book

There are many human cancers which actively synthesize specific characteristic proteins such as melanomas, thyroid cancer and squamous cell carcinoma. Many cancer researchers have of course tried to utilize this specific activity as a key for the selective treatment of cancers. In the past for example, the molecular hybrid compound of DOPA, a substrate of melanin, and nitrogen mustard N-oxide hydrochloride, a ctyotoxic anti-tumor drug, was synthesized as Melphalan and used to treat malignant melanoma. A major problem arose though in that it was soon found to be highly suppressive toward bone marrow and quite toxic while not being remarkably effective. Thus, malignant melanoma could not be cured by it. Such failure led us to develop a novel bimodal therapeutic system which includes the use of non-toxic potentially cytocidal chemicals which selectively accumulate within the cancer cells and which are converted by a controllable modality into an actively cytocidal element in situ. We can now non-surgically cure malignant melanoma and glioblastoma with our selective cancer treatment, neutron capture therapy (NCT); as can be found in this volume. Included are 124 papers on the latest breaking developments discussed at the Sixth International Symposium on NCT for Cancer held in Kobe during the late autumn of 1994.

Editors and Affiliations

  • Mishima Institute for Dermatological Research, Kobe, Japan

    Yutaka Mishima

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation